Flexible, portable medical diagnostic devices are the future, augmenting equity and access to quality healthcare. That means designing for patients as well as caregivers, creating devices that are intuitive, easy to use, and easily adaptable to various environments.
Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.
Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.
New KFF focus groups revealed that some thought the process of renewing Medicaid coverage during the unwinding of the continuous enrollment provision was simple. Others, however, faced challenges with communication from state Medicaid agencies, and some weren't aware their coverage had been terminated.
Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.